PMID- 27259948
OWN - NLM
STAT- MEDLINE
DCOM- 20170202
LR  - 20181113
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 16
DP  - 2016 Jun 4
TI  - Protective effect of etanercept, an inhibitor of tumor necrosis factor-alpha, in a 
      rat model of retinal ischemia.
PG  - 75
LID - 10.1186/s12886-016-0262-9 [doi]
LID - 75
AB  - BACKGROUND: To assess the neuroprotective effect of etanercept (Enbrel(R)) which is 
      a commercialized Tumor necrosis factor-alpha (TNF-alpha) inhibitor on axonal injury in an 
      animal model of acute ischemia. METHODS: Acute ischemia was induced by 
      intraocular pressure elevation in 36 rats. The treatment groups underwent 
      subcutaneous injection of etanercept (0.3 or 1.0 mg/kg) three times per week up 
      to 4 weeks. The control groups were treated in the same manner using the same 
      volume of phosphate-buffered saline (PBS). Optic nerve damage was evaluated by 
      counting the number of axons under a transmission electron microscope. Microglial 
      cell activity was assessed using Iba1 and CD68. RESULTS: After induction of 
      ischemia, the ratio of preserved axons was significantly greater in the 2-week 
      1.0-mg/kg etanercept-treated group than in the PBS-treated group (p = 0.062). The 
      4-week 0.3-mg/kg and 1.0-mg/kg etanercept-treated groups also showed 
      significantly higher ratios of preserved axons than did the PBS-treated group 
      (p = 0.021 and 0.003, respectively). The expression of Iba1 and CD68 in the optic 
      nerve was lower in the etanercept-treated groups than in the PBS-treated groups. 
      Immunohistochemical staining using rabbit anti-Iba1 antibody showed that the 
      amount of microglia at the optic nerve head was noticeably lower in the 
      etanercept-treated groups than in the PBS-treated groups. CONCLUSIONS: Etanercept 
      significantly suppressed optic nerve injury in this rat model of acute ischemia. 
      This in vivo study suggests that etanercept might be a novel neuroprotective 
      treatment agent for TNF-alpha-related disease.
FAU - Bae, Hyoung Won
AU  - Bae HW
AD  - Department of Ophthalmology, Severance Hospital, Institute of Vision Research, 
      Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 
      South Korea.
FAU - Lee, Naeun
AU  - Lee N
AD  - Department of Ophthalmology, Hallym Hospital, Incheon, South Korea.
FAU - Seong, Gong Je
AU  - Seong GJ
AD  - Department of Ophthalmology, Severance Hospital, Institute of Vision Research, 
      Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 
      South Korea.
FAU - Rho, Seungsoo
AU  - Rho S
AD  - Department of Ophthalmology, CHA Bundang Medical Center, CHA University, 
      Seongnam, South Korea.
FAU - Hong, Samin
AU  - Hong S
AD  - Department of Ophthalmology, Severance Hospital, Institute of Vision Research, 
      Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 
      South Korea.
FAU - Kim, Chan Yun
AU  - Kim CY
AD  - Department of Ophthalmology, Severance Hospital, Institute of Vision Research, 
      Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 
      South Korea. kcyeye@yuhs.ac.
LA  - eng
PT  - Journal Article
DEP - 20160604
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Disease Models, Animal
MH  - Etanercept/*therapeutic use
MH  - Humans
MH  - Immunohistochemistry
MH  - Ischemia/*drug therapy/etiology
MH  - Male
MH  - Neuroprotective Agents/*therapeutic use
MH  - Optic Nerve Diseases/*drug therapy/etiology/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Retinal Diseases/*drug therapy/pathology
MH  - Retinal Ganglion Cells/drug effects/pathology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
PMC - PMC4893298
OTO - NOTNLM
OT  - Acute ischemia
OT  - Axonal injury
OT  - Etanercept
OT  - Microglia
OT  - Tumor necrosis factor-alpha
EDAT- 2016/06/05 06:00
MHDA- 2017/02/06 06:00
PMCR- 2016/06/04
CRDT- 2016/06/05 06:00
PHST- 2015/08/18 00:00 [received]
PHST- 2016/05/28 00:00 [accepted]
PHST- 2016/06/05 06:00 [entrez]
PHST- 2016/06/05 06:00 [pubmed]
PHST- 2017/02/06 06:00 [medline]
PHST- 2016/06/04 00:00 [pmc-release]
AID - 10.1186/s12886-016-0262-9 [pii]
AID - 262 [pii]
AID - 10.1186/s12886-016-0262-9 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2016 Jun 4;16:75. doi: 10.1186/s12886-016-0262-9.